TaiMed Biologics’ Board of Directors has approved a strategic investment in Marigold Therapeutics, further expanding its footprint in Antibody-Drug Conjugate (ADC) new drug development. Marigold is an ADC focused biotech company with a core ADC technology platform designed to address current limitations in ADCs. The founding team has extensive experience in the development of numerous ADC molecules, of which several are already in the clinical stage of development. Marigold is backed by a stable equity structure consisting of multiple notable biotech firms and venture capital investors. By combing Marigold’s advanced ADC platform and experience with TaiMed Biologics’ expertise in antibody development and manufacturing, the partnership is poised to create significant synergies and accelerate the development of next-generation ADC therapies.
ADCs represent a rapidly emerging approach in global antibody drug innovation, leveraging the high specificity of antibody molecules to deliver potent small-molecule payloads directly to targeted disease sites. Once localized, these payloads are released to maximize therapeutic efficacy while minimizing off-target effects. This targeted strategy has proven especially promising for difficult-to-treat conditions, positioning ADCs at the forefront of cutting-edge drug development.
Dr. Jimmy Chang, PhD, Chief Executive Officer of TaiMed Biologics, commented:
“The ADC market holds immense potential, with an estimated compound annual growth rate of 15% to 20%. In 2024, TaiMed Biologics officially integrated ADC technology into our R&D pipeline, successfully developing a First-in-Class ADC platform focused on precision HIV therapy. This platform holds broad applicability across a range of disease areas, and we anticipate exploring and expanding its use to other viral diseases and immunology-related conditions. Our collaboration with Marigold not only strengthens TaiMed Biologics’ ADC capabilities, but also opens new opportunities for joint initiatives in antibody product development and manufacturing, reinforcing our commitment to bringing transformative therapies to patients worldwide.”
About TaiMed Biologics
TaiMed Biologics (4147.TWO), founded in 2007 in Taiwan, is a leading commercial-stage biotechnology company dedicated to developing innovative therapies for HIV treatment. TaiMed successfully developed ibalizumab (Trogarzo®), the first-in-class monoclonal antibody for HIV, which received U.S. FDA approval in 2018. The company is also focused on developing long-acting biologics and antibody-drug conjugates (ADC) for HIV therapy.
In addition to its R&D efforts, TaiMed offers comprehensive contract development and manufacturing (CDMO) services to pharmaceutical clients. The company has been publicly traded on the OTC Market since November 2015 and is currently part of the MSCI Small Cap Index.
About Marigold Therapeutics
Marigold Therapeutics was founded at the end of year 2024. Marigold Therapeutics focuses on the development of Antibody-Drug Conjugates (ADC) as its core business. The company is headquartered in the Cayman Islands. In its initial phase, it will leverage global portfolio allocation to embrace CDMO/CRO industry chain and accelerate product development while simultaneously building a research and development team in Taiwan, aiming to become a world-class biopharmaceutical company.